Atorvastatin has antithrombotic effects in patients with type 1 diabetes and dyslipidemia
| Autor: | N. Håkan Wallén, Peter Henriksson, Pia Santesson, Ulf Adamson, Sara Tehrani, Gun Jörneskog, Fariborz Mobarrez, Aleksandra Antovic, Per-Eric Lins |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Adult
Blood Platelets medicine.medical_specialty Time Factors Atorvastatin Fibrinogen Tissue plasminogen activator Fibrin Thromboplastin chemistry.chemical_compound Thrombin Double-Blind Method Fibrinolytic Agents Cell-Derived Microparticles Internal medicine Plasminogen Activator Inhibitor 1 medicine Humans Pyrroles Aged Dyslipidemias Glycated Hemoglobin Sweden Cross-Over Studies biology PROTHROMBIN FRAGMENT 1.2 Integrin beta3 Thrombosis Hematology Middle Aged P-Selectin C-Reactive Protein Diabetes Mellitus Type 1 Treatment Outcome Endocrinology chemistry Heptanoic Acids Plasminogen activator inhibitor-1 biology.protein Hydroxymethylglutaryl-CoA Reductase Inhibitors Plasminogen activator Biomarkers medicine.drug |
| Zdroj: | Thrombosis Research. 126:e225-e231 |
| ISSN: | 0049-3848 |
| Popis: | Introduction Diabetes is a prothrombotic state involving a more thrombogenic fibrin network. In the present study we investigated the effects of lipid-lowering therapy with atorvastatin on fibrin network structure and platelet-derived microparticles in patients with type 1 diabetes and dyslipidemia. Materials and Methods Twenty patients were treated with atorvastatin (80 mg daily) or placebo during 2 months in a randomized, double-blind, cross-over study. Fibrin network permeability, expression of glycoprotein IIIa, P-selectin and tissue factor on platelet-derived microparticles, plasma endogenous thrombin potential, plasminogen activator inhibitor-1 and tissue plasminogen activator antigen levels were assessed. Additionally, levels of plasma fibrinogen, high-sensitivity C-reactive protein and glycated haemoglobin were measured. Results During treatment with atorvastatin, fibrin network permeability increased (p = 0.01), while endogenous thrombin potential and expression of glycoprotein IIIa, P-selectin and tissue factor decreased (p In vitro experiments indicated that platelet-derived microparticles influence the fibrin network formation as fibrin network permeability decreased significantly when platelet-derived microparticles were added to normal plasma. Baseline levels of plasminogen activator inhibitor-1 and tissue plasminogen activator antigen as well as plasma fibrinogen and high-sensitivity C-reactive protein were within reference values and not significantly changed during atorvastatin treatment, while glycated haemoglobin increased 0.3% (p Conclusions Novel treatment effects were found in patients with type 1 diabetes and dyslipidemia during atorvastatin therapy, i.e. a more porous fibrin network, to which reduced expression of glycoprotein IIIa, P-selectin and tissue factor on platelet-derived microparticles may contribute. The observed impairment of glycemic control during long-term statin treatment deserves attention. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect